Particle.news

Download on the App Store

Scientists Develop Broad-Spectrum Snake Antivenom Using Human Antibodies

A groundbreaking antivenom derived from Tim Friede's unique immunity neutralizes venom from 19 deadly elapids, with researchers advancing toward trials in animals and humans.

Tim Friede with a water cobra.
Study coauthors Mark Bellin and Hannah Hirou prepare antivenom during the course of the research.
Tim Friede, center, with colleagues Mark Bellin, right, Joel Andrade, left, Gengan Li, back left, and Nicholas Bayless, back center.
Image

Overview

  • Tim Friede's 18-year self-immunization with venom from 16 lethal snake species led to the discovery of two broadly neutralizing antibodies in his blood.
  • The antivenom cocktail, combining these antibodies with the toxin inhibitor varespladib, fully protects mice against venom from 13 elapid species and offers partial protection for six more.
  • Researchers aim to refine the formula by adding a fourth component and extend coverage to viperid snakes, another major venomous family.
  • Veterinary trials in Australia are being planned, with the eventual goal of conducting human trials to confirm the antivenom's efficacy and safety.
  • The approach addresses limitations of traditional antivenoms, which are species-specific, animal-derived, and prone to adverse reactions, offering hope for a universal treatment.